Early trial tests new drug combo for Tough-to-Treat cancers
NCT ID NCT01374620
Summary
This early-stage study aimed to find the safest and most effective dose of a two-drug combination (paclitaxel and cyclophosphamide) for people with advanced cancer who had run out of standard treatment options. It involved 28 adult participants to test how well they tolerated the treatment and to see if it could help control their cancer. The main goal was to identify the highest dose that could be given without causing severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Oscar Lambret
Lille, 59000, France
Conditions
Explore the condition pages connected to this study.